Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (Pts) with advanced cancer

被引：0
|
作者：
Schilsky, R. L.
Geary, D.
Skoog, L.
Desai, A.
Valickas, J.
Masson, E.
Laurent, D.
Pendowski, C.
Vokes, E.
Ratain, M.
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Novartis Oncol, E Hanover, NJ USA
[3] Schering AG, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3595
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis
    Langenberg, M. H.
    Witteveen, P. O.
    Lankheet, N.
    Roodhart, J. M.
    Rosing, H.
    Beijnen, J. H.
    Voest, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC).
    Koch, I
    Baron, A
    Roberts, S
    Junker, U
    Palacay-Ramona, M
    Masson, E
    Kay, A
    Wiedenmann, B
    Laurent, D
    Cebon, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 341S - 341S
  • [33] A phase I/II trial of single-agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM)
    Yung, W. K. Alfred
    Friedman, H.
    Reardon, D.
    Provenzale, J.
    Jackson, E.
    Serajuddin, H.
    Laurent, D.
    Chen, B.
    Conrad, C.
    ANNALS OF ONCOLOGY, 2004, 15 : 207 - 207
  • [34] A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer.
    Kuo, T.
    Fitzgerald, A.
    Kaiser, H.
    Sikic, B. I.
    Fisher, G. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
  • [35] Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation
    Zips, D
    Krause, M
    Hessel, F
    Westphal, J
    Brüchner, K
    Eicheler, W
    Dörfler, A
    Grenman, R
    Petersen, C
    Haberey, M
    Baumann, M
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3869 - 3876
  • [36] Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC).
    Trarbach, T
    Schleucher, N
    Tewes, M
    Seeber, S
    Junker, U
    Laurent, D
    Vanhoefer, U
    Masson, E
    Lebwohl, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 272S - 272S
  • [37] Phase I/III study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.
    Schleucher, N
    Trarbach, T
    Junker, U
    Tewes, M
    Masson, E
    Lebwohl, D
    Seeber, S
    Laurent, D
    Vanhoefer, U
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 259S - 259S
  • [38] Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma
    Brander, Danielle M.
    Beaven, Anne W.
    Gockerman, Jon P.
    Diehl, Louis F.
    Gasparetto, Cristina
    Shea, Thomas C.
    deCastro, Carlos
    Moore, Joseph O.
    Rizzieri, David A.
    BLOOD, 2012, 120 (21)
  • [39] Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo
    Banerjee, Susana
    A'Hern, Roger
    Detre, Simone
    Littlewood-Evans, Amanda J.
    Evans, Dean B.
    Dowsett, Mitchell
    Martin, Lesley-Ann
    CLINICAL CANCER RESEARCH, 2010, 16 (16) : 4178 - 4187
  • [40] Modulation of tumor hypoxia in response to treatment with ionizing radiation and the VEGFR-inhibitor PTK787/ZK222584
    Riesterer, O
    Honer, M
    Oehler, C
    Djonov, V
    Bodis, S
    Jochum, W
    Ametamey, S
    Pruschy, M
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S328 - S328
12345